Krawitt EL (1996) Autoimmune hepatitis. N Engl J Med 334(14):897–903

CAS  Article  Google Scholar 

Manns MP, Lohse AW, Vergani D (2015) Autoimmune hepatitis—update 2015. J Hepatol 62(1 Suppl):S100–S111

Article  Google Scholar 

Vergani D et al (2004) Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 41(4):677–683

Article  Google Scholar 

Homberg JC et al (1987) Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology 7(6):1333–1339

CAS  Article  Google Scholar 

Czaja AJ et al (1995) Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol 23(1):32–38

CAS  Article  Google Scholar 

Wies I et al (2000) Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355(9214):1510–1515

CAS  Article  Google Scholar 

Montano-Loza AJ et al (2012) Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 32(1):85–92

CAS  Article  Google Scholar 

Hoeroldt B et al (2011) Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 140(7):1980–1989

Article  Google Scholar 

Mack CL et al (2019) Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology, .

European Association for the Study of the L (2015) EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol, 63(4): p. 971–1004.

Soloway RD et al (1972) Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63(5):820–833

CAS  Article  Google Scholar 

Alvarez F et al (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31(5):929–938

CAS  Article  Google Scholar 

Manns MP et al (2010) Diagnosis and management of autoimmune hepatitis. Hepatology 51(6):2193–2213

CAS  Article  Google Scholar 

Dhaliwal HK et al (2015) Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol 110(7):993–999

CAS  Article  Google Scholar 

Ishak K et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22(6):696–699

CAS  Article  Google Scholar 

Lohse AW et al (2020) Second-line and third-line therapy for autoimmune hepatitis a position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Journal of hepatology.

Miyake Y et al (2005) Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 43(6):951–957

CAS  Article  Google Scholar 

Zachou K et al (2016) A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther 43(10):1035–1047

CAS  Article  Google Scholar 

Zachou K et al (2011) Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 55(3):636–646

CAS  Article  Google Scholar 

Santiago P et al (2019) Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther 49(7):830–839

CAS  Article  Google Scholar 

Kanzler S et al (2001) Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol, 39(5): p. 339–41, 344–8.

Lüth S et al (2008) Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 42(8):926–930

Article  Google Scholar 

Czaja AJ, Carpenter HA (2004) Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40(4):646–652

CAS  Article  Google Scholar 

Czaja AJ (2014) Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther 39(4):385–406

CAS  Article  Google Scholar 

Kirstein MM et al (2015) Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 62(5):1524–1535

CAS  Article  Google Scholar 

Nicoll AJ et al (2019) Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Aliment Pharmacol Ther 49(10):1314–1322

CAS  Article  Google Scholar 

van den Brand FF et al (2019) Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis. Clin Gastroenterol Hepatol, 17(5): p. 940–947 e2.

Czaja AJ (2009) Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 51(1):161–167

CAS  Article  Google Scholar 

Pape S et al (2020) Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 months. Clin Gastroenterol Hepatol, 18(7): p. 1609–1617 e4.

Sebode M, Schramm C (2015) AIH: which alternative for difficult-to-treat patients? Dig Dis 33(Suppl 2):83–87

Article  Google Scholar 

Hartl J et al (2015) Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol 62(3):642–646

CAS  Article  Google Scholar 

Moon AM et al (2020) Immunosuppression in autoimmune hepatitis: is there an end game? Am J Gastroenterol 115(4):498–501

Article  Google Scholar 

Yoshizawa K et al (2012) Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 56(2):668–676

Article  Google Scholar